Featured Products:

Featured Articles:






Meropenem for Injection (500mg and 1g).


Meropenem for injection is a sterile, pyrogen-free, synthetic, ultra-broadspectrum, Carbapenem antibiotic for intravenous administration. It is Chemically (4R,5S,6S)-3-[[(3S,5S)-5-(Dimethylcarbamoyl)-3-pyrrolidinyl]thio]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1 azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid trihydrate.

Meropenem penetrates well into most body fluids and tissues including cerebrospinal fluid, achieving concentrations matching or exceeding those required to inhibit most susceptible bacteria.


Meropenem is a broad-spectrum carbapenem antibiotic. It is active against Gram-positive and Gram- negative bacteria.

The bactericidal activity of Meropenem results from the inhibition of cell wall synthesis. Meropenem readily penetrates the cell wall of most Gram-positive and Gram-negative bacteria to reach penicillin- binding-protein (PBP) targets. Its strongest affinities are toward PBPs 2, 3 and 4 of Escherichia coli and Pseudomonas aeruginosa; and PBPs 1, 2 and 4 of Staphylococcus aureus.

Meropenem has significant stability to hydrolysis by beta-lactamases of most categories, both penicillinases and cephalosporinases produced by Gram-positive and Gram-negative bacteria. Meropenem has significant stability to hydrolysis by beta-lactamases of most categories, both penicillinases and cephalosporinases produced by Gram-positive (exept methicillin-resistant staphylococci (MRSA)) and Gram-negative bacteria. In vitro tests show meropenem to act synergistically with aminoglycoside antibiotics against some isolates of Pseudomonas aeruginosa.


Skin and Skin Structure Infections: Complicated skin and skin structure infections due to Staphylococcus aureus (beta-lactamase and non-beta- lactamase producing, methicillin susceptible isolates only), Streptococcus pyogenes, Streptococcus agalactiae, viridans group streptococci, Enterococcus faecalis (excluding vancomycin-resistant isolates), Pseudomonas aeruginosa, Escherichia coli, Proteus mirabilis , Bacteroides fragilis, and Peptostreptococcus species.

Intra-Abdominal Infections: Complicated appendicitis and peritonitis caused by viridans group streptococci, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Bacteroides fragilis, B. thetaiotaomicron, and Peptostreptococcus species.

Bacterial Meningitis (Pediatric patients - 3 months only): Bacterial meningitis caused by Streptococcus pneumoniae, Haemophilus influenzae (beta-lactamase and non-beta-lactamase-producing isolates), and Neisseria meningitidis. Meropenem has been found to be effective in eliminating concurrent bacteremia in association with bacterial meningitis.


Route of Adminstration: For I.V. use only

MEROSAN is given intravenously as the trihydrate, but doses are expressed in terms of the amount of anhydrous meropenem. 1.14 g of meropenem trihydrate is approximately equivalent to 1 g of anhydrous meropenem. It is given by slow injection over 3 to 5 minutes or by infusion over 15 to 30 minutes in a usual adult dose of 0.5 to 1 g every 8 hours, increased to 2 g every 8 hours for meningitis; doses of up to 2 g every 8 hours have also been used in cystic fibrosis.

In Renal Impairment: Children over 3 months of age and weighing less than 50 kg may be given 10 to 20 mg/kg every 8 hours, increased to 40 mg/kg every 8 hours for meningitis. Dose of 25 to 40 mg/kg every 8 hours have been used in children with cystic fibrosis.

Direction For Reconstitution: MEROSAN is to be constituted using the volumes of diluent as shown below.


For Intravenous Administration: Constitute 1 g Meropenem For Injection with 20 ml Sterile Water for Injection.

For Infusion: 1 g Meropenem For Injection may be directly constituted with a compatible diluent fluid.

Compatible Diluent Fluids:
  • Sodium Chloride Injection 0.9%
  • Dextrose Injection 5.0%
  • Dextrose Injection 10.0%
  • Dextrose and Sodium Chloride Injection 5.0% / 0.2%
  • Dextrose and Sodium Chloride Injection 5.0% / 0.9%
  • Potassium Chloride in Dextrose Injection 0.15% / 5.0%
  • Sodium Carbonate in Dextrose Injection 0.02% / 5.0%
  • Dextrose and Sodium Chloride Injection 2.5% / 0.45% Mannitol
  • Mannitol Injection 2.5%
  • Ringers Injection
  • Ringers Lactate Injection
  • Sodium Lactate Injection 1/6 N
  • Sodium Bicarbonate Injection 5.0%
Adverse Effects: Meropenem may cause side effects such as thrombocythaemia, headache, nausea, vomiting, diarrhoea, abdominal pain, increase in serum transaminases, alkaline phosphatase, lactic dehydrogenase, skin rashes, pruritis, inflammation, pain at site of administration.

Contraindications: MEROSAN is contraindicated in patients with a history of allergic reactions to any of the penicillins, cephalosporins, or Beta-lactamase inhibitors.

Presentation: MEROSAN for Injection is available as Box of one vial (500mg- 10ml Vial, 1g- 20ml Vial).

Important: The drug information on this Web page is meant to be educational. It is not a substitute for medical advice. Please see your health care professional for more information about your specific medical condition and the use of the above mentioned drug.
  Home | About Us | Global Presence | Healthcare Products | Q & C | Manufacturing | Group Of Companies | News | Career | Contact Us  
  Copyright © 1995-2010 SRS PHARMACEUTICALS PVT. LTD. Website Design and Developed by Miracleworx Web Solutions Pvt. Ltd.  |  Sitemap